English: Scheme of a chloroplast. Français : Schéma d’un chloroplaste. (Photo credit: Wikipedia)
Scientists are reporting an advance in re-engineering photosynthesis to transform plants into bio-factories that manufacture high-value ingredients for medicines, fabrics, fuels and other products.
They report on the research in the journal ACS Synthetic Biology
Poul Erik Jensen and colleagues explain that photosynthesis does more than transform carbon dioxide and water into sugar and oxygen and generate energy. That process also produces a wealth of natural chemical compounds, many of which have potential uses in medicines and other commercial products. However, evolution has compartmentalized those functions into two separate areas of plant cells. Chloroplasts, the packets of chlorophyll that make plants green, generate energy and produce sugar and oxygen. Another structure, the endoplasmic reticulum, produces a wide range of natural chemicals.
Their report describes breaking that evolutionary compartmentalization by relocating an entire metabolic pathway needed for production of natural bioactive chemicals to the chloroplast. “This opens the avenue for light-driven synthesis of a vast array of other natural chemicals in the chloroplast,” they say, citing key natural chemicals that would be ingredients in medications.
The authors acknowledge funding from the Villum Fonden and the Danish Agency for Science, Technology and Innovation.
The Latest Bing News on:
Re-engineering photosynthesis
- Vacuuming CO2 ‘least bad’ climate engineering optionon May 8, 2021 at 4:50 pm
So-called negative emissions technologies (NETs) have gone mainstream among climate scientists. They mostly hate the idea of re-engineering the planet to control temperatures, but they fear the ...
The Latest Google Headlines on:
Re-engineering photosynthesis
[/vc_column_text]
The Latest Bing News on:
Bio-factories
- Bio-Rad Launches CFX Duet Real-Time PCR Systemon May 27, 2022 at 2:44 am
Bio-Rad Laboratories, Inc. has announced the launch of the CFX Duet Real-Time PCR System to support researchers in developing singleplex and duplex quantitative PCR (qPCR) assays.
- New Zealand's Humble Bee Bio is using bees to create bioplasticson May 26, 2022 at 7:40 am
The CTO also said fashion brands have been reaching out to Humble Bee Bio. Environmental sustainability has become a priority for apparel companies, particularly when it comes to responsible and ...
- Bio-Based Resins Market Size 2022 with 16.23% CAGR : Innovation Strategies & Recent Industry Developments With Top Players and Forecast Up to 2028on May 25, 2022 at 9:29 pm
Based Resins Market” 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028 The global Bio-Based Resins market is expected to register a significant CAGR 16.23% during the forecast ...
- CJ BIO and NatureWorks Working Towards a Master Collaboration Agreement to Commercialize Novel Biopolymer Solutionson May 25, 2022 at 7:00 am
Companies announce signed letter of intent to collaborate on creating advanced products based on industry-leading Ingeo™ PLA and PHACT® PHA technologies to meet growing demand for sustainable ...
- Bio-based chemicals Size 2021 | Industry Growth, Share, Trends, Demand and Forecast to 2030on May 23, 2022 at 5:40 pm
Global Bio-based chemicals Market to surpass USD 191.8 billion by 2031 from USD 76.1 billion in 2021 at a CAGR of 9.7% in the coming years, i.e., 2021-2031 Fatpos Global added a new report into their ...
- Global Circular and Bio-based Materials Market 2022 Size, Share, Applications, Advance Technology and Top Companies to 2028on May 22, 2022 at 4:27 pm
The research studies Global Circular and Bio-based Materials Market posted by MarketsandResearch.biz offer market geography and prospects. It also covers the most significant aspects of the global ...
- Kronos Bio Inc. [KRON] Is Currently -5.59 below its 200 Period Moving Avg: What Does This Mean?on May 20, 2022 at 10:07 am
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced participation in the H.C. Wa ...
- Vyant Bio to Present at the H.C. Wainwright Global Investment Hybrid Conferenceon May 19, 2022 at 5:32 am
Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT), is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company ...
- Inceptor Bio Announces $37 Million Series A Financing to Develop Cell Therapies for Difficult-to-Treat Cancerson May 19, 2022 at 4:44 am
Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, today announced the closing of a $37 million Series A financing led by Kineticos Ventures. Proceeds from ...
- Triangle cell therapy startup Inceptor Bio closes $37M in Series A fundingon May 19, 2022 at 4:30 am
Cell and gene therapy startup Inceptor Bio, which raised $26 million in seed capital not long ago, has added more than $37 million in Series A funding.
